

November 23, 2001

Endo Pharmaceuticals, Inc.
Attention: Carol Patterson
500 Endo Blvd.
Garden City, NY 11530

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated April 6, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for two additional strengths of Percocet® Tablets; e.g., Percocet Tablets 7.5 mg/325 mg and Percocet Tablets 10 mg/325 mg (Oxycodone Hydrochloride and Acetaminophen Tablets USP).

Submission of this ANDA is based upon a Suitability Petition submitted pursuant to 21 CFR 314.93 and approved by the agency on September 9, 2000 (Docket No. 00P-1270/CP1).

Reference is also made to your amendment dated September 14, 2001.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The drug products, Percocet® Tablets 7.5 mg/325 mg and Percocet Tablets 10 mg/325 mg (Oxycodone Hydrochloride and Acetaminophen Tablets USP), 7.5 mg/325 mg and 10 mg/325 mg, respectively, can be expected to have the same therapeutic effect as equivalent doses of the listed drug product upon which the Agency relied as the basis of safety and effectiveness. Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research